UK health minister says data on Pfizer vaccine supports shift to 12-week dosing schedule



© Reuters. Britain’s Health Secretary Hancock holds news conference in London

LONDON (Reuters) – Data supports Britain’s decision to move to a 12-week dosing schedule for Pfizer (NYSE:)’s COVID vaccine, health minister Matt Hancock said on Thursday, adding details on efficacy gathered during the rollout would be published as soon as possible.

“Around 89% efficacy comes from between days 14 and days 21 after the first dose,” Hancock told lawmakers, saying he had reviewed the data, and that it supported the decision to move to a 12-week schedule between doses.

“We’re looking at this data, and in fact we’re measuring the efficacy here at home for those who’ve been vaccinated, by matching the data between those who’ve been vaccinated and those who test positive. And we’re monitoring that and we will publish that data as soon as it is clinically valid.”

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

READ  Facebook met UK officials three times before Libra announcement





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here